These challenges might be addressed by i) the development of a TEDbody carrying multiple epitope peptides to broaden the range of cancer patients that can be treated with this modality, and ii) combination therapy with either a cytokine (e.g., IFN-γ) or an appropriate chemical agent to restore MHC-I expression on tumor cells [52, 53]. This evidence concerns the gene IFNG and neoplasm.